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Abstract
Background: Parkinson’s disease (PD) is a chronic, neurodegenerative disorder affecting over 137,000 people in the
UK and an estimated five million people worldwide. Treatment typically involves long-term dopaminergic therapy,
which improves motor symptoms, but is associated with dose-limiting side effects. Developing effective complementary,
non-pharmacological interventions is of considerable importance. This paper presents the protocol for a three-arm pilot
study to test the implementation of computer-based cognitive training that aims to produce improvements
or maintenance of motor slower and motor fatigue symptoms in people with PD. The primary objective is to
assess recruitment success and usability of external data capture devices during the intervention. The secondary
objectives are to obtain estimates of variance and effect size for changes in primary and secondary outcome
measures to inform sample size calculations and study design for a larger scale trial.
Methods: The study aims to recruit between 40 and 60 adults with early- to middle-stage PD (Hoehn and Yahr
1–3) from National Health Service (NHS) outpatients’ clinics and support groups across North Wales, UK. Participants
will be randomised to receive training over five sessions in either a spatial grid navigation task, a sequential subtraction
task or a spatial memory task. Patient-centred outcome measures will include motor examination scores from part 3 of
the UPDRS-III and data from movement kinematic and finger tapping tasks.
Discussion: The results of this study will provide information regarding the feasibility of conducting a larger
randomised control trial of non-pharmacological cognitive interventions of motor symptoms in PD.
Trial registration: ISRCTN, ISRCTN12565492. Registered 4 April 2018—retrospectively registered, in accordance
with the WHO Trial Registration Data Set.
Keywords: Parkinson’s disease, Cognition, Computerised cognitive training, Non-pharmacological intervention,
Motor symptoms, Fatigue, Feasibility trial
* Correspondence: psp0a1@bangor.ac.uk; Charles.Leek@liverpool.ac.uk
1School of Psychology, Bangor University, Brigantia Building, Penrallt Road,
Bangor, Gwynedd LL57 2AS, UK
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Payne et al. Pilot and Feasibility Studies           (2018) 4:190 
https://doi.org/10.1186/s40814-018-0375-4
Parkinson’s disease (PD) is a chronic, neurodegenerative
disorder affecting over 137,000 people in the UK and an
estimated five million worldwide [1]. It largely reflects
dopaminergic cell loss in the basal ganglia and consequent
disruption to ganglia-thalamo-cortical motor circuits, in-
cluding the supplementary motor area [2, 3]. The primary
symptoms of PD are motor in nature (bradykinesia,
tremor, rigidity, balance and gait disturbance), but are
known to be accompanied with, and at times preceded by,
cognitive impairments, including psychomotor slowing
[4]. In the absence of a cure for the illness, a major chal-
lenge is to find interventions to ameliorate these debilitat-
ing motor symptoms. For most people with PD, treatment
typically involves long-term dopaminergic therapy, which
is associated with a range of dose-limiting complications,
and considerable healthcare costs (which exceed £3.3b an-
nually in the UK alone [5]). In this context, the prospect of
developing effective complementary, non-pharmacological
interventions is of considerable importance [6, 7]. Such in-
terventions offer the prospect of better long-term clinical
management of motor symptoms, improving quality of life
and reduced healthcare costs.
The goal of this study is to begin to address this
challenge by piloting a novel, hypothesis-driven, non-
pharmacological intervention to improve motor function
and diminish motor fatigue in PD. This novel approach is
based on the use of hypothesis-driven cognitive task inter-
ventions to stimulate the motor system and ameliorate
motor symptoms. It is important to note that this tech-
nique differs from cognitive stimulation (or so-called brain
training) interventions that aim to increase resilience to
cognitive—rather than motor—decline in illnesses such as
dementia. Physiotherapy and occupational interventions
including motor cueing used in conjunction with walking
aids, gait training, regular exercise and dance can produce
benefits for people with PD [8–10]. There is also a grow-
ing interest in the development of other approaches to the
treatment of motor symptoms including, for example,
neuro-feedback training based on real-time functional
brain imaging [11–13], and other techniques based on
cortical excitation induced by transcranial magnetic
stimulation (TMS) [14–16]. These latter techniques,
whilst showing considerable promise, are limited in a
number of ways: They are unlikely to be cost-effective
for large numbers of participants, and their suitability is
limited to people who are able to undergo scanning (or
procedures such as TMS), for whom these methods
pose no health risk, and to individuals who are willing
to undergo the procedure. To our knowledge, there have
been no systematic attempts to investigate the potential
use of targeted cognitive-behavioural interventions for the
treatment of motor dysfunction. However, advances in our
knowledge about the functional neuro-anatomy of the
brain, and of the underlying neuropathology of PD,
suggest that such an investigation is well motivated on sci-
entific grounds, is timely and has the potential to deliver
significant healthcare benefits.
This novel approach is inspired by recent neurosci-
ence insights into the functional links between the sup-
plementary motor area (SMA) (a key component of the
motor system in the human brain) and specific cogni-
tive processes. The background to the current project
stems from an established body of work from our own,
and other research groups, on the neural substrates of
high-level visuospatial processing in the neurologically
normal brain [17–20]. Previously, we have shown that
visuospatial processing is supported by a network of re-
gions including the posterior parietal cortex (PPL),
dorso-lateral prefrontal cortex (DLPFC) and the SMA.
This is most clearly shown by functional imaging studies
of brain activity during the performance of visuospatial
tasks like mental rotation or mental grid navigation [21].
Several studies, including work in our own lab, have
shown that people with PD are impaired in visuospatial
tasks like mental rotation and grid navigation [22, 23].
Furthermore, the magnitude of impairment in mental
rotation is dependent on angular disparity: people with
PD show slower rates of mental rotation consistent with
impairment to visuospatial processes. This is consistent
with what we know about the underlying neuropathol-
ogy of PD. PD is linked to dopaminergic nigrostriatal
cell loss and deregulation of neurotransmitter activity in
the nigrostriatal pathways of the basal ganglia. This is
thought to disrupt basal ganglia-thalamo-cortical motor
circuits including the SMA [24].
A key theoretical question is why visuospatial tasks like
mental rotation, and grid navigation, should activate re-
gions such as the SMA—an area traditionally associated
with the planning and execution of movement [17,
25]—even when the tasks are configured to require
no overt motor response [21]. One hypothesis is that
visuospatial tasks, and prehensile movement, draw on cer-
tain shared underlying functional processes that are sup-
ported by an overlapping cortical network including the
SMA. For example, both tasks involve spatial transform-
ation, that is, the computation of mappings between
spatial locations. In the case of movement, this is required
to calculate the direction and distance (i.e. vector) be-
tween the current hand location and a to-be-grasped ob-
ject (e.g. when reaching for a cup). During mental rotation
(or grid navigation), the same abstract computation may
be used to calculate the angular distance between two fea-
tures of a rotated object or the direction and distance re-
quired to map from one grid location to another.
Interestingly, other evidence supporting this putative func-
tional link between movement and visuospatial processing
comes from behavioural studies showing interference be-
tween simultaneous performance of manual and mental
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rotation tasks [26, 27] and from studies of visuospatial pro-
cessing impairments in PD [22, 23, 28]. By targeting these
cognitive processes, we can, in principle, stimulate function-
ing of these regions and ameliorate motor performance.
We have previously examined this possibility in a local
NHS-funded pilot study (BCUHB 05/WNo03/27; unpub-
lished). Sixteen people with early-stage (H&Y 1/2) PD,
tested during the ‘ON’ phase, with age-matched controls,
completed a visuospatial ‘intervention’ task of mental grid
navigation and a control task of sequence memory, in two
separate sessions, a week apart. Immediately before and
after the two tasks, we obtained precise measures of
movement onset delay and velocity with a simple reaching
task completed on a touch-sensitive screen. There were
no significant changes in movement onset time, or vel-
ocity following either tasks, in the control group. How-
ever, the people with PD showed a reduction in motor
performance in the simple reaching task (slower mean
onset and velocity) following the control task, but an
enhancement of motor performance following the
visuospatial task (faster mean onset and velocity). This
pattern was found in 12/16 (75%) participants. These
data provide some evidence that the performance of
cognitive tasks that involve visuospatial processing—
even after a single 20-min session—can enhance resili-
ence to motor slowing and improve motor function, re-
ducing hypokinesia and bradykinesia. As a form of
hypothesis-driven cognitive intervention for motor dys-
function, this approach could potentially have signifi-
cant clinical benefits for people with PD. If effective,
the approach could form the basis of a low-cost, non-
pharmacological, treatment that could be made access-
ible to large numbers of people in the form of a port-
able software/web-based programme of exercises for
home use.
Before the intervention can be considered for a large-
scale clinical trial, we first need to better understand the
size and robustness of effects in larger samples and assess
its clinical significance—whether the intervention leads to
levels of improvement in movement onset and velocity
that are of benefit to people with PD and whether the ben-
efits to motor function extend to other aspects of the ill-
ness such as reduced rigidity and increased motor fluency.
This pilot trial will examine these issues and further
our understanding of the potential of this novel ap-
proach to the treatment of motor dysfunction in PD.
This research will form a vital step in evaluating the
clinical significance of the approach, its suitability as
an intervention for people with PD and the feasibility
of a future large-scale clinical trial.
Aims
The primary aim of this pilot study is to test the implemen-
tation of a computer-based cognitive training intervention
designed to impact on motor slowing and motor fatigue
symptoms in people with PD. We aim to explore the
impact of exposure to five sessions of a spatial grid
navigation intervention task in the hope that it could
improve these symptoms, relative to two other control
tasks: sequential subtraction and spatial memory.
Primary objective
Feasibility for a larger scale RCT will be determined based
on the following:
 Recruitment: Successful recruitment and retention of
a minimum of 30 participants for the full intervention
within a 12-month funding period (currently reduced
to 6months active testing/recruitment, following
IRAS application and successful research passport
application). If this is not possible, we would need
to re-evaluate recruitment practices and adjust the
timeline of future studies to reflect the challenges
faced. This may require identification of additional
resource implications in terms of researcher/staff
time, costings, length of the intervention and delivery
methods.
 Acceptability/usability: Evaluation of the usability of
the external devices used to capture movement
kinematic (button box) and finger tapping data
(modified touchscreen gloves). In evaluating utility
of custom data capture devices, we will pay particular
attention to any failures/limitations in data capture
(e.g. proportional data loss, reliability/consistency of
measures). Additionally, we will pay attention to any
difficulties that participants may experience using the
equipment following informal discussion at the close
of the study that may aid in the re-design of key
equipment. This will be necessarily open-ended and
will not rely on formal qualitative analysis.
Secondary objective
Estimation of variance and effect sizes to inform power
calculations for larger scale RCTs for primary and sec-
ondary outcome measures:
 A clinically relevant change in UPDRS-III motor
examination scores of at least 5 points from pre
to post measurements in response to spatial grid
navigation training relative to the other control tasks.
 Improvement in movement kinematic response
times over the course of the five intervention
sessions in response to spatial grid navigation
training relative to the other control tasks.
 Improvement in motor fatigue measures over the
course of the five intervention sessions in response
to spatial grid navigation training relative to the
other control tasks.
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Methods
Study design
We aim to conduct a three-arm, parallel, single-blind,
randomised pilot trial, comparing the effect of five ses-
sions of training on one of three cognitive intervention
tasks. An adapted CONSORT (Consolidated Standards
of Reporting Trials) study flow diagram is presented in
Fig. 1.
Study settings
Participants will be recruited from Movement Disorders
outpatients’ clinics (Betsi Cadwaladr University Health
Board, North Wales) and through direct contact follow-
ing an earlier press release. We anticipate that most par-
ticipants will prefer to be tested in their own homes, but
all participants will be offered the option of being tested
at local hospitals or at the School of Psychology, Bangor
University. Participants will complete the study without
modification to their medication or additional therapy
regimens (e.g. physiotherapy, speech and language), and
the study will be conducted to ensure maximum flexibil-
ity for all participants.
Study participants
Adults with a diagnosis of Parkinson’s disease will be re-
cruited for this study. The first participant enrolled in
the study on 16/03/2018. To date, 10 (25% of 40) partici-
pants have completed the study and a further six have
recently enrolled.
Inclusion criteria
Participants of any age or sex are eligible to take part
providing they meet the following criteria:
 Diagnosis of Parkinson’s disease in accordance with
UK Brain Bank Diagnostic Criteria [29]
 Hoehn and Yahr stage 1–3 [30]
 Ability to give informed consent
 Montreal Cognitive Assessment [31, 32] score > 24
Exclusion criteria
 Clinical diagnosis of dementia
 History of other significant neurological conditions
 Presence of visual hallucinations
 Cognitive impairment (MoCA score ≤24)
 Significant visual impairment affecting viewing of a
computer screen
Primary clinical outcome measures
The change in the motor examination score from the
Unified Parkinson’s Disease Rating Scale - III (UPDRS - III;
[33]) from Session 1 to Session 5.
Secondary outcome measures
 Motor fatigue: Changes in the finger tapping count,
the time between taps (kinesia measures) and tap
dwell time (akinesia)
Fig. 1 Protocol study flow diagram
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 Motor slowing: Changes in the response latencies
(total movement time, movement initiation time
and velocity) on the movement kinematic task
Participant enrolment
Clinical determination of eligibility for the study will be
assessed by Dr. John Hindle (JVH), a Consultant Geria-
trician with expertise in movement disorders, and a
team of other movement disorder specialists. Initial con-
tact with eligible participants about the study will be
made by a member of the research team (JP) present at
clinics or via phone. In the absence of JP at clinics, the
clinical studies officer and/or clinician will seek consent
from interested participants to pass contact details onto
the research team. Participants will have a minimum of
72 h to consider the study information once they have
received the participant information sheet. An initial ap-
pointment will be arranged for participants to give in-
formed consent, to complete the MoCA [31, 32] and
other background questionnaires.
Randomisation
Unique participant ID numbers were generated using
IDGenerator software [34] with a 2:1:1 ratio for Grid
Navigation to Subtraction to Spatial Memory (respectively
n = 20, 10, 10) tasks for the initial 40 participants with the
aim of achieving a 1:1:1 ratio dependent on recruitment
success (n = 20 per treatment). ID numbers were rando-
mised based on a sequence of random numbers. Partici-
pants were allocated an ID number based on this pre-
defined allocation order at the point of giving informed
consent. ID numbers and allocation to condition for par-
ticipants 41–60 will be generated using the same protocol,
ensuring that participants are blind to the content of other
conditions until debriefing. JP is responsible for gener-
ation, allocation and assignment to interventions.
Blinding
This study is conducted single blind, in the sense that
participants will not be made aware until debriefing
which of the intervention conditions was expected to
affect movement kinematic and motor fatigue symp-
toms. Double blinding is almost impossible in a cogni-
tive intervention of this nature where the researcher is
responsible for the setup and delivery of tasks in the
presence of the participant. Data analysis will not be
undertaken by an independent statistician, but once data
has been compiled, we intend to pass anonymised raw
data to an independent researcher who will generate
new random IDs for all participants and revalue the
intervention conditions. Our colleague will retain the
linked information for all groups and new ID numbers
until data analysis is completed.
Intervention
Participants will be randomised to receive training over
five sessions on Spatial Grid Navigation, Sequential Sub-
traction or Spatial Memory intervention tasks. Sequential
Subtraction activates SMA to a similar extent as Spatial
Grid Navigation, and we might expect that the sequential
processing component could generalise to produce a simi-
lar improvement in movement kinematic and motor fa-
tigue symptoms that we observed in an earlier pilot study.
The spatial memory task is visually identical to the other
two tasks but does not include a visuospatial sequencing
component, acting as a neutral baseline task. The time
between sessions will be dependent upon the availabil-
ity of participants, and we will endeavour to work
around participants’ other commitments and activities,
as flexibly as possible to maximise retention. The vari-
ability in the time between sessions is a potential vari-
able of interest, as the relative intensity may moderate
the effectiveness of the intervention. We anticipate that
participants will prefer to be tested in their own homes,
but we are able to test people in the School of Psych-
ology or in offices at local hospitals.
Assessment measures
Figure 2 provides a schematic overview of computer-
based tasks and intervention tasks.
Background measures
We will administer a series of background measures
which enable us to provide a detailed description of our
sample and individual symptomatic profile. In the first
session, participants will give informed consent and will
complete the following tasks and questionnaires:
 Montreal Cognitive Assessment 7.1 (MoCA; [31]).
A score > 24 is needed to continue with the study.
Participants will be told that we are looking for
participants who score within a certain range to
make sure that the tasks are suitable. If this is not
achieved, participants will be debriefed and asked if
they would like to be contacted about other ongoing
studies and consent will be sought to relay their
interest to the clinical studies officer. JP was assessed
conducting the MoCA by a clinical neuropsychologist
(RC), and all of the MoCA tests will be second-scored
for inter-rater reliability by RC.
 Demographics questionnaire: sex, education,
employment history and experiences of PD
symptoms.
 Edinburgh Handedness Inventory [35] as a measure
of hand dominance, to account for known advantages
in motor tasks for the dominant hand and as an
additional potential moderator of performance if
the dominant hand is most affected by PD.
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 Parkinson’s disease quality of life—short form (PDQ-8
[36]) as a general measure of quality of life.
 Parkinson’s Fatigue Scale (PFS-16 [37]) as a global
measure of fatigue.
 Non-motor symptoms questionnaire (NMS [38])
to provide a global overview of PD symptomatology
outside of the motor domain. The severity of non-
motor symptoms could influence the efficacy of the
intervention.
 Parkinson’s Disease Sleep Scale (PDSS [39]) to
measure overall perceived sleep quality, which
contributes to cognitive performance.
Primary objective: feasibility assessment
Recruitment
Recruitment refers to the total number of participants
who completed five intervention sessions. To determine
feasibility, we expect a minimum of 30 participants to
have been recruited and completed the sessions by the
close of the study period.
Acceptability/usability
Usability will be assessed in terms of the fidelity of the
data. We will report proportional data loss for each of the
secondary measures outlined below and as consistency/re-
liability of the captured data. A high proportional data loss
or low reliability would indicate a need for revision of de-
vice designs or protocols in explaining their use. In terms
of acceptability, we will pay particular attention to any dif-
ficulties that participants may face over the course of the
study and conduct an informal discussion to gather opin-
ions about potential improvements. However, because of
the lack of expected depth in these responses, we do not
intend to conduct formal qualitative analyses.
Secondary objectives
Primary clinical outcome measure
The motor examination from part 3 of the Unified Par-
kinson’s Disease Rating Scale-III [33] will be the primary
clinical outcome measure for this study. The UPDRS will
be administered to all participants by JP at the beginning
of experimental session 1 and the end of experimental
session 5. JP has received training and supervision at
outpatients’ clinics from JVH. UPDRS motor assess-
ment at both time points will be video recorded for
all participants and 20% will be blind-rated by a neur-
ologist (GD) for inter-rater reliability, excluding scores
for tone/rigidity.
Secondary patient-centered outcome measures
Both secondary measures will be assessed before and
after the intervention task administered in each session.
All tasks are coded in OpenSesame 3.2.1 [40] and run
on a Dell Inspiron 15 5000 series touchscreen laptop
(1920 × 1080 resolution, 15.6″ screen). Hand/arm order
was counterbalanced between administrations, within
sessions (e.g. pre: L-R; post: R-L) and between tasks (e.g.
finger tapping L-R; pointing R-L).
Fig. 2 Schematic overview of each of the computer-based tasks
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Finger tapping Finger tapping performance is used
routinely in clinical practice to assess the presence and
severity of bradykinesia in people with PD but is often
restricted to the count/number of taps, which provides
only limited information (e.g. [41]). Objective, multi-
variate measures of tapping performance that quantify
the speed and variability of performance as well as tap
frequency are needed in addition to clinical assessment.
Our measures of finger tapping are influenced by those
collected from the recently developed BRAIN (BRady-
kinesia-Akinesia INcoordination) test, recently vali-
dated for assessment of bradykinesia in PD [42, 43]. At
the beginning of the trial, the BRAIN test was not avail-
able for general use. As such, we collect detailed response
data from the standard single-digit finger tapping task in-
cluded as part of the UPDRS-III, using pairs of modified
touchscreen gloves. These gloves are a practical, low-cost
measurement device that preserves natural motion. Each
contact of the conductive pads on the thumb and index
finger registers as a left or right mouse click for the re-
spective hand. Each trial begins with a 3-s countdown,
followed by the word ‘TAP!’ which cues the action and
stays on the screen for 15 s. Each hand will be tested
separately with the wrist resting against the table and
the other hand laid flat. Kinesia is measured as the
number of taps over 15 s and the time between taps.
The dwell time for each tap is collected, as a measure
of akinesia. Lower values or increased variance for
kinesia measures would reflect worse performance, in-
dicating more motor fatigue, whereas lower values for
akinesia measures would reflect less motor fatigue, as
participants are able to reliably disengage from the
movement. We will also be able to calculate a slope of
performance for each hand as a profile measure for the
number of taps per second as a more specific measure
of fatiguing bradykinesia.
Movement kinematics In people with PD, movement
kinematic measures of velocity and trajectory are im-
paired relative to healthy controls [44, 45] and changes
in the measures in response to an intervention may
index subtle targets for rehabilitative efforts. In our sim-
ple pointing task, participants must press down and hold
a button on a custom-made USB response box for 4000
ms. Three red circles, 2° (102px, 57 cm) in diameter, are
displayed in an arc at left [(− 750px, − 47px) ≈ (13°, 0.85°)
from centre], centre [(0px, − 325px) ≈ (0°, 6°)] and right lo-
cations [(750px, − 47px) ≈ (13°, 0.85°) from centre]. Partic-
ipants continue to hold down the response button until
one of the circles turns green at a variable SOA of 750ms,
1500ms and 2250ms. Participants will be instructed to
make a reaching movement to touch the green target as
fast and as accurately as possible, before returning their
hand to the response box (they do not have to touch the
button to end the trial). Each participant will wear a
pair of touchscreen-compatible gloves to neutralise dif-
ferences in skin conductivity. To minimise strain on the
wrist, a mousepad with gel wrist support will be placed
under the response box. There are 18 trials per hand.
The primary outcome measure on this task is action
completion time (touch response time − target onset
time) and was the primary dependent variable in our
pilot study using an analogue version of the task. The
action completion time can be decomposed into two
separate elements: movement initiation time (key re-
lease time − target onset time) and reaching time/vel-
ocity (touch response time − initiation time), which
could reflect subtle targets for improvement of motor
slowing in adults with PD. In addition, we collect mea-
surements of accuracy of the touch response and devi-
ation from the centre of the target on each trial as a
measure of incoordination.
Intervention tasks
Target positions in the start and test grids of the tasks
described below were identical across tasks. Five inde-
pendent blocks of trials were generated and counterba-
lanced between sessions and participants using a 5 × 5
Latin square to mitigate any potential bias in the se-
quence generation process. Two blocks of 18 trials are
administered with a self-paced break in between. All
tasks were programmed in OpenSesame 3.2.1 [40]. To
avoid contamination of motor fatigue and motor slow-
ing measures, responses are made verbally in all three
intervention tasks. Responses are recorded by OpenSe-
same via a small cardioid lapel microphone and stored
as individual wave files. Response times are then ex-
tracted offline using the VoiceKey programme for Win-
dows command line [46] or manually verified using
Praat [47] in the case of any errors/noise spikes.
Spatial grid navigation
On each trial, participants see an empty grid made up of
nine squares, subtending 10° visual angle for 1600 ms. A
start square, highlighted in red, is displayed for 2500ms,
and participants are told to hold the position of the start
square in memory. A sequence of five screens are dis-
played (1500 ms + 100ms blank ISI) showing sequences
of two, three or four arrows (subtending 4°), interspersed
with grey hash marks as placeholders. The arrows indi-
cate movement of the red starting square by one space
in any of the four cardinal directions (up, down, left,
right), restricted within the boundaries of the grid. No
movements are made to the placeholders. Participants
must track the position of the red square based on the
observed sequence, in their minds eye. At the end of the
sequence, a test grid is presented with a target square
highlighted in blue. Participants must decide if the
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position of the blue test square is consistent with the final
position of the presented sequence (50:50 same-different).
Participants make a vocal ‘same’ or ‘different’ response
whilst the test grid is on the screen (3000 ms).
Control group A: sequential subtraction
A minimum of 10 (up to maximum of 20) participants
will be enrolled into this arm of the study, dependent on
recruitment success. The trial sequence for this task is
identical to the spatial grid navigation task with a few
modifications. The start square is replaced with a num-
ber highlighted in red. The arrows in the sequence were
replaced with the numbers 1–9, which had to be sequen-
tially subtracted from the start number before deciding
whether the test number, presented in blue, was the
same or different as the final total in the sequence. Se-
quences varied in length from two to four numbers, plus
between one and three placeholders.
Control group B: spatial memory
A minimum of 10 (up to maximum of 20) participants
will be enrolled into this arm of the study, dependent
on recruitment success. This task contains no spatial
sequencing component and will provide a pure baseline
for the present study. In this task, participants see a
start square, highlighted in red, and are told to hold its
position in memory for a duration of two to four suc-
cessive placeholders (1600 ms ea.) before a test grid ap-
pears with a square highlighted in blue. Participants are
instructed to verbally report whether the test grid is in
the ‘same’ or ‘different’ position to the start grid.
Procedure
This protocol was written in accordance with the CON-
SORT [48] SPIRIT guidelines (Standard Protocol Items:
Standards of Reporting Trials) [49] for pilot and feasibil-
ity trials and the TIDieR guidelines (Template for Inter-
vention Description and Replication) [50] for reporting
of complex interventions. A SPIRIT table is presented as
Table 1, and the SPIRIT and TIDieR checklists are avail-
able as Additional files 1 and 2. When the results are
known, we will submit the final manuscript in accord-
ance with the CONSORT and TIDieR guidelines. JP is a
research project support officer with a background in
experimental psychology and clinical interventions in
stroke. JP will be responsible for the organisation and
delivery of the intervention, including scheduling par-
ticipants, gaining written informed consent, face-to-
face task administration, data management and debrief-
ing. Following initial contact, participants will be given
a minimum of 72 h to consider whether they would like
to take part. Participants give informed consent and
complete the MoCA and background assessments in
the initial session (− t1, SPIRIT table), which will take
no longer than 1 h. Each participant will take part in
five intervention sessions with a minimum frequency of
approximately one session per week. The time between
sessions will vary and is dependent on the availability of
individual participants. We take a flexible approach to
encourage engagement and reduce attrition. Providing
there is sufficient variability, we intend to explore the
effect of intervention intensity as a moderator in our
analyses. The motor examination from part 3 of the
UPDRS-III will be administered at the beginning of ses-
sion 1 (t1) and the end of session 5 (t5). Secondary
movement kinematic and finger tapping measures will
be administered before and after the administration of
the intervention tasks in every session and presented in
a fixed order of finger tapping, followed by movement
kinematics. In each session, we will collect information
on time since last dose of medication, hours and quality
of sleep (1 = very poor; 10 = excellent). A rating of fatigue
(1 = no fatigue/full of energy; 10 = absolutely drained) will
be taken at the beginning of each task to monitor within
and between-session fluctuation. Session 1 and session 5
will take up to 75min to complete, dependent on breaks
and progress through tasks, but sessions 2–4, which in-
clude only computer tasks, will take between 45 and 60
min per session. Participants will be debriefed and offered
the opportunity to provide feedback on the intervention/
tasks at the end of session 5.
Sample size
The target sample size for this study is between 40 and
60 participants. On the basis of our previous work, we
estimate an attrition rate of 20%. Participants who are
unable to complete the study or withdraw for any reason
will be replaced. The target sample estimate is based on
a maximum sample that we can reasonably expect to ob-
tain over a 9–12-month active recruitment period, given
the population and both clinical and research resources
available.
Statistical methods
Summary statistics for demographic and background in-
formation will be reported for all participants in each of
the three groups. Presented figures will endeavour to
provide an overview of individual data points as well as
measures of central tendency, variance and 95% confi-
dence limits. Exploratory analyses exploring the relation-
ships between participant characteristics, intervention
intensity and primary/secondary outcomes will be con-
ducted to inform future work. With sufficient participants,
mixed effects analyses will be applied to secondary out-
come measures and intervention data, to identify potential
patterns of effects, which will enable us to characterise
both within- and between-subject variances. The analyses
are primarily designed to support descriptive analysis of
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data and inform future power calculations for analyses of
this type. Interpretation of patterns of data will be caution-
ary and based upon estimates of confidence to guide fu-
ture hypothesis testing.
Data handling and storage
Identifying participant information will be stored in a
password-protected database on an external, encrypted
hard disc. Additionally, the IDgenerator [34] software
creates layered ID numbers linking an ID paired with
identifying information in a separate password-protected
database to an ID number associated with study data
using a third, temporary ID. At the close of the study, this
link will be erased and identifying information will be
destroyed. Over the course of the study, electronic data
will be stored on a password-protected laptop with an ac-
tive firewall and anti-virus. Regular backups of electronic
data will be made on an encrypted external hard drive and
Table 1 Schedule of enrolment, interventions and assessments
aDelivered twice per session, pre and post intervention tasks. Finger tapping is always administered before movement kinematics
**The time between sessions will be variable, in keeping with participants’ schedules and other commitments
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automatically uploaded to a protected web server. During
transport between sites, anonymised participant packs and
the laptop will be locked in a file box, in a locked car boot.
Consent forms and completed participant packs will be
stored in a locked file cabinet in a locked office at Ban-
gor University. All data will be kept for 10 years follow-
ing final access.
Auditing
The project will be subject to independent auditing by
Betsi Cadwaladr University Health Board as the funding
body and by Bangor University as the sponsor. The trial
team will meet quarterly to discuss the trial progress
and/or modifications. Regular updates will be sent out to
all members of the team, as well as the clinical studies
officer assisting with recruitment.
Harms
This is non-Clinical Trial of an Investigational Medicinal
Product (non-CTIMP) and as such poses minimal risk
to participants, and it is not necessary to institute a for-
mal data management committee. We do not anticipate
any adverse or serious adverse events will arise during
the course of the study. Reporting of such events will be
carried out in accordance with NHS policies. Worsening
symptoms of PD, hospital stays for elective treatment for
pre-existing medical conditions or death resulting from
PD will not be reported as SAEs.
Protocol version
This paper is based on protocol version 4.0 (30/01/2018).
Any amendments will be communicated with the study
team and addressed in a final published manuscript once
results are known.
Dissemination
The data will be presented at national and international
conferences and published in peer-reviewed journals.
The headline results of the study will be shared with par-
ticipants at the close of the study and made available to
the wider public through national bodies (e.g. Parkin-
son’s Disease UK).
Discussion
The protocol described is hypothesis-driven, founded on
previous pilot data from an independent group of people
with PD and underpinned by a considerable body of
work which supports the link between activation of the
SMA and visuospatial processing. Our previous data
demonstrated a significant improvement in measures of
movement kinematics and motor fatigue following a
single administration of the spatial navigation task.
However, the question remains whether repeated expos-
ure to the same intervention would result in a cumulative
improvement or support maintenance of current func-
tioning, providing the basis for the future development
of this non-pharmacological cognitive intervention. If
we observe the expected effects, we would utilise the
data for a formal power calculation to inform a large-
scale RCT. The longer-term view is to develop an evi-
dence-based, online or app-based platform that could be
accessed by people in their own homes alongside other
pharmacological or physical treatments to support main-
tenance of motor slowing and motor fatigue symptoms.
An app-based or online portal would enable automatic al-
location to intervention condition and complete double
blinding of the intervention conditions and concealment
during data analysis stage.
As it currently stands, the study protocol is restricted
to early-middle disease stage for adults with good cogni-
tive function. This feasibility trial will enable us to refine
procedures and task instructions to maximise accessibil-
ity and engagement with the tasks, which can be further
developed for application to the broadest possible sam-
ple. In the face of favourable results, future directions
should include longer term follow-up and tracking of
motor decline in people with PD. The results from this
study will provide valuable insight into the feasibility of
cognitive interventions of this type and generate/refine
hypotheses for future studies.
Additional files
Additional file 1: SPIRIT 2013 Checklist. (DOC 121 kb)
Additional file 2: The TIDieR (Template for Intervention Description and
Replication) checklist. (DOCX 31 kb)
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